Fatma Suna KIRAÇ, Olga YAYLALI, Doğangün YÜKSEL

The role of 18F-FDG PET-CT in the detection of unknown primary malignancy: a retrospective study

Background/aim: This study aimed to retrospectively evaluate the role of 18F-FDG PET/CT imaging in the detection of unknown primary tumor sites in patients with a suspicious malignancy. Materials and methods: We retrospectively examined the 18F-FDG PET/CT images of 50 unknown primary malignancy patients. The malignancy of the lesions with increased 18F-FDG uptake on PET images was defined by interpreting the nondiagnostic CT images that were obtained with the PET study. The primary tumor site was decided according to the combined PET/CT findings, and the results were subsequently confirmed with a histopathological examination. Results: Fifty patients (29 M; 21 F) aged 18 85 years were included in the study. The sample included 32 malignant and 18 benign lesions according to the histopathological evaluation. 18F-FDG PET/CT study accurately identified malignant lesions in 28 (average SUVmax ± SD: 8.27 ± 7.22) and benign lesions in 12 (average SUVmax ± SD: 3.63 ± 3.07) patients; these findings were histopathologically confirmed. PET/CT correctly detected the primary tumor site in 16 (50%) of 32 patients. Conclusion: 18F-FDG-PET/CT identified the primary tumor site well in 50% of our cases. We propose that 18F-FDG PET/CT imaging may help to accurately detect malignant lesions in patients with unknown primary tumors.

PDF

___

1. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of unknown primary. Eur J Cancer 2003; 39: 19902005.
2. Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol 2007; 46: 592601.
3. Chorost MI, Lee MC, Yeoh CB, Molina M, Ghosh BC. Unknown primary. J Surg Oncol 2004; 87: 191203.
4. Le Chevalier T, Cvitkovic E, Caille P, Harvey J, Contesso G, Spielmann M, Rouesse J. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med 1988; 148: 20352039.
5. Naresh KN. Do metastatic tumours from an unknown primary reflect angiogenic incompetence of the tumour at the primary site? A hypothesis. Med Hypotheses 2002; 59: 357360.
6. Kaya AO, Coskun U, Unlu M, Akdemir UO, Ozdemir NY, Zengin N, Benekli M, Yildiz R, Yaman E, Ozturk B et al. Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin. Asian Pac J Cancer Prev 2008; 9: 683686.
7. Ambrossini V, Nanni C, Rubello D, Moretti A, Battista G, Castellucci P, Farsad M, Rampin L, Fiorentini G, Franchi R et al. 18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin. Radiol Med 2006; 111: 11461155.
8. Pelosi E, Pennone M, Deandreis D, Douroukas A, Mancını M, Bisi G. Role of whole body positron emission tomography/ computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging 2006; 50: 1522.
9. Delgado-Bolton RC, Fernandez-Perez C, Gonzales-Mate A, Carreras JL. Meta-analysis of the performance of 18F-FDG PET in primary tumour detection in unknown primary tumors. J Nucl Med 2003; 44: 13011314.
10. Gutzeit A, Antoch G, Kuhl H, Egelhof T, Fischer M, Hauth E, Goehde S, Bockisch A, Debatin J, Freudenberg L. Unknown primary tumors: detection with dual-modality PET/CT initial experience. Radiology 2005; 234: 227234.
11. Reske SN, Kotzerke J. FDG PET for clinical use: results of the 3rd German Interdisciplinary Concensus Conference, OncoPET III, 21 July and 19 September 2000. Eur J Nucl Med 2001; 28: 17071723.
12. Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol 2009; 19: 731744.
13. Bohuslavizki KH, Klutmann S, Kroger S, Sonnemann U, Buchert R, Werner JA, Mester J, Clausen M. FDG PET detection of unknown primary tumors. J Nucl Med 2000; 41: 816822.
14. Haas I, Hoffmann TK, Engers R, Ganzer U. Diagnostic strategies in cervical carcinoma of an unknown primary (CUP). Eur Arch Otorhinolaryngol 2002; 259: 325333.
15. Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, Merrouche Y, Laplanche A, Fizazi K. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002; 20: 46794683.
16. Fencl P, Belohlavek O, Skopalova M, Jaruskova M, Kantorova I, Simonova K. Prognostic and diagnostic accuracy of [18F] FDG-PET/CT in 190 patients with carcinoma of unknown primary. Eur J Nucl Med Mol Imaging 2007; 34: 17831792.
17. Nassenstein K, Veit-Haibach P, Stergar H, Gutzeit A, Freudenberg L, Kuehl H, Fischer M, Barkhausen J, Bockisch A, Antoch G. Cervical lymph node metastases of unknown origin: primary tumor detection with whole-body positron emission tomography/computed tomography. Acta Radiol 2007; 48: 11011108.
18. Nanni C, Rubello D, Castellucci P, Farsad M, Franchi R, Toso S, Barile C, Rampin L, Nibale O, Fanti S. Role of F-18 FDG PETCT imaging for the detection of an unknown primary tumor: preliminary results in 21 patients. Eur J Nucl Med Mol Imaging 2005; 32: 589592.
19. Freudenberg LS, Fischer M, Antoch G, Jentzen W, GutzeitA, Rosenbaum SJ, Bockisch A, Egelhof T. Dual modality of F-18 fluorodeoxyglucose-positron emission tomography/ computed tomography in patients with cervical carcinoma of unknown primary. Med Princ Pract 2005; 14: 155160.
20. Alberini JL, Belhocine T, Hustinx R, Daenen F, Rigo P. Whole body positron emission tomography using fluorodeoxyglucose in patients with metastases of unknown primary tumours (CUP syndrome). Nucl Med Commun 2003; 24: 10811086.
21. Yapar Z, Kibar M, Yapar AF, Paydas S, Reyhan M, Kara O, Buyukdereli G, Aydin M, Kelle AP, Unal I et al. The value of 18F-fluorodeoxyglucose positron emission tomography/ computed tomography in carcinoma of an unknown primary: diagnosis and follow-up. Nucl Med Commun 2010; 31: 5966.
22. Seve P, Billotey C, Brouselle C, Dumontet C, Mackey JR. The role of 2- deoxy-2-(F-18)fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007; 109: 292299.
23. Kole AC, Nieweg OE, Pruim J, Hoekstra HJ, Koops HS, Rooedenburg JL, Vaalburg W, Vermey A. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998; 82: 11601166.
24. Fleming AJ Jr, Smith SP Jr, Paul CM, Hall NC, Daly BT, Agrawal A, Schuller DE. Impact of [18F]-2-fluorodeoxyglucosepositron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 2007; 117: 11731179.
25. Kwee TC, Basu S, Cheng G. FDG PET/CT in carcinoma of unknown primary. Eur J Nucl Med Mol Imaging 2010; 37: 635644.
26. Al-Brahim N, Ross C, Carter B, Chorneyko K. The value of postmortem examination in cases of metastasis of unknown origin-20-year retrospective data from a tertiary care center. Ann Diagn Pathol 2005; 9: 7780.
27. Blaszyk H, Hartmann A, Bjornsson J. Cancer of unknown primary: clinicopathologic correlations. APMIS 2003; 111: 10891094.
28. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. RadioGraphics 1999; 19: 6177.
29. Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET CT system: initial results. Radiology 2002; 225: 575581.
30. Pelosi E, Messa C, Sironi S, Picchio M, Landoni C, Bettinardi V, Gianolli L, Maschio AD, Gilardi MC, Fazio F. Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Imaging 2004; 31: 932939.
31. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008; 49: 480508.
32. El-Haddad G, Alavi A, Mavi A, Bural G, Zhuang H. Normal variants in [18F]-fluorodeoxyglucose PET imaging. Radiol Clin North Am 2004; 42: 10631081.
33. Wartski M, Le Stanc E, Gontier E, Vilain D, Banal A, Tainturier C, Pecking AP, Alberini JL. In search of an unknown primary tumour presenting with cervical metastases: performance of hybrid FDG-PET_CT. Nucl Med Commun 2007; 28: 365371.